- Abigail Coursolle
- Alejandra Pavisich
- Alejandra Pavisich
- Alexis Robles-Fradet
- Alicia Emanuel
- Allyson Crays
- Amanda Avery
- Amani Echols
- Amy Chen
- Andy DiAntonio
- Arielle Linsey
- Ash Bliss
- Brian Brooks
- Briana Torres
- Brit Vanneman
- Brit Vanneman
- California Policy Team
- Candace Gibson
- Carly Myers
- Cassandra LaRose
- Cat Duffy
- Catherine McKee
- Cathren Cohen
- Charlie Blodnieks
- Charly Gilfoil
- Cheyenne Peters
- Christina Piecora
- Corey Davis
- Dania Douglas
- Daniel Young
- David Machledt
- Deanna Hartog
- Dylan de Kervor
- Elizabeth Edwards
- Elizabeth G. Taylor
- Elizabeth Zirker
- Emma Parker-Newton
- Eskedar Girmash
- Fabiola De Liban
- Fabiola De Liban
- Georgesula Ziama
- Geraldine Doetzer
- Geron Gadd
- Hannah Eichner
- Hayley Penan
- Héctor Hernández-Delgado
- Ian Anderson
- Ian McDonald
- Jane Perkins
- Jasmine Young
- Jennifer Cannistra
- Jennifer Lav
- Joe McLean
- Jules Lutaba
- Kally Xu
- Kasey Nichols
- Katy DeBriere
- Kavisha Prajapati
- Kimberly Lewis
- Leonardo Cuello
- Liz McCaman Taylor
- Madeline Morcelle
- Mara Youdelman
- Margaret Okakpu
- Maya Levin
- Michelle Lilienfeld
- Michelle Yiu
- Miriam Delaney Heard
- Mizue Suito
- Priscilla Huang
- Rachel Holtzman
- Rachel Utz
- Rolonda Donelson
- Sarah Grusin
- Sarah Somers
- Shandra Hartly
- Shandra Hartly
- Skyler Rosellini
- Steven Schmidt
- Susan Berke Fogel
- T. Nancy Lam
- Walter Hsiang, MD
- Wayne Turner
- Zamir M. Brown
- Show all
- Alabama
- Alaska
- All United States
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- National
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- Show all
- 1557
- 50th Anniversary
- Abortion
- Admin and Procedural Barriers
- ADS Evergreen
- Affordable Care Act
- Assisted Reproduction
- Automated Decision Making
- Behavioral Health
- Child and Adolescent Health
- CHIP
- Civil Procedure
- Civil Rights
- Coronavirus
- Cost-sharing
- Court Access
- COVID-19 Public Health Emergency
- Data Collection
- Defending Medicaid
- Delivery System Featured
- Delivery System Reform
- Demonstrations
- Disability
- Disability Rights
- Doula Care
- Dual Eligible Beneficiaries
- Eligibility and Enrollment
- EPSDT
- Exchanges/Marketplaces
- Family Planning
- Federal and State Court Cases
- Foster youth
- Foster Youth - Advocates
- Foster Youth - Consumers
- HCBS/LTSS
- Health Care Reform
- Health Care Refusals
- Health Disparities
- Health Reform
- HIV/AIDS and Sexual Health
- Home and Community Based Services
- Immigrant Health
- Language Access
- LGBTQ Health
- Litigation
- Managed Care
- Marketplace - California
- Medi-Cal
- Medicaid
- Medicaid Awareness Month
- Medicaid Awareness Month 2024
- Medicaid Defense 2025
- Mental Health
- Nondiscrimination
- Opioid Use Disorder
- Oral Health
- Post-OBBBA Medi-Cal Defense (California)
- Post-OBBBA Medicaid & ACA Defense
- Pregnancy
- Prescription Drugs Marketplace
- Prescription Drugs Medicaid
- Privacy and Confidentiality
- Protect Medicaid 2023
- Public Charge
- Public Health
- Refusals of SRH Care
- Reproductive Health
- Services
- Sexual and Reproductive Health (SRH)
- Sexual Health
- SRH Equity
- SRH Equity for Immigrants
- SRH Equity for LGBTQI+ People
- SRH Equity for People of Color
- SRH Equity for People with Disabilities
- SRH Equity for Young People
- SRH Nondiscrimination
- SRH Post-OBBBA
- Supreme Court
- Telehealth
- Telehealth Abortion Coverage
- Waivers and Demonstrations
- Women's Health
- Work Requirements
- December 8, 2020
Testimony on the Hyde Amendment before the House Subcommittee on Labor, Health and Human Services, Education, and Related Agencies
Read moreThe National Health Law Program (NHeLP) submitted this testimony to the House Committee on Appropriations’ Subcommittee on Labor, Health and Human Services, Education, and Related Agencies' hearing on "The Impact on Women Seeking an Abortion but are Denied Because of an Inability to Pay." We advocate for Medicaid policies…
- December 3, 2020
NHeLP Comments on HHS Regulations Rule (aka SUNSET Rule)
Read moreIn the Regulations Rule, HHS seeks to retroactively impose a mandatory expiration date on an estimated 18,000 duly promulgated regulations. Even long-standing rules would be automatically rescinded unless they survive a complex process of assessment and review. Programs like Medicaid and the Children's Health Insurance Program (CHIP) could be…
- November 30, 2020
Abortion is Health Care
Read moreThe National Health Law Program believes that abortion is health care and should be covered and accessible like any other medical intervention. This issue brief examines a brief history of abortion in the United States, defines abortion procedures as common and safe medical interventions, presents the myriad of populations…
- November 10, 2020
California Policy Needs During COVID and Beyond: Reproductive and Sexual Health
Read moreCOVID-19 has changed the landscape for reproductive and sexual health care services, delivery, and access. As has been the case across the board, the COVID-19 pandemic has laid bare racial and socioeconomic inequities, and in many cases exacerbated them. At the same time, the challenges raised by the pandemic…
- October 19, 2020
What Public Charge Means for Reproductive Justice
Read moreUpdate: As of March 9, 2021, the Trump-era public charge regulations are no longer in effect. The Biden administration published a final rule on March 15, 2021 formally removing the Trump-era public charge rule and restoring the long-standing 1999 Field Guidance as the standing public charge policy. The administration has significant work…
September 17, 2020NHeLP comments on Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”)
Read moreThe Orange Book is an important and informative drug resource for a range of stakeholders. In a request for comments, FDA seeks feedback on the types of people or entitles using the Orange Book, additional information and features to incorporate into the Orange Book, and therapeutic equivalence information. NHeLP…